NutrientsOct 16, 2026

GLP-1 Treatments and Muscle Health in Obesity: Body Weight, Muscle Strength, and Muscle Loss Outcomes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 17, 2026

Abstract

GLP-1-based pharmacotherapies may impact sarcopenia risk through various mechanisms.

Preclinical studies suggest that GLP-1-based treatments may improve insulin sensitivity and reduce inflammation.
Some studies indicate a potential for muscle loss or protein breakdown associated with these therapies.
Clinical data show greater reductions in fat mass compared to fat-free or lean mass, which does not exclusively indicate changes in skeletal muscle.
Direct assessments of muscle health and function in clinical studies are limited and show mixed outcomes.
The relationship between GLP-1-based therapies and incident sarcopenia is rarely examined.
Current evidence does not provide a clear conclusion regarding the overall effect of these therapies on sarcopenia risk.

Simplified

Background: Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intramuscular fat may be beneficial. Objective: This narrative review evaluated the effects of GLP-1-based pharmacotherapies on body composition, muscle quantity, composition and function, and their potential role in sarcopenia. Methods: PubMed and Google Scholar were searched for clinical and experimental studies published primarily between 2016 and 2026. Results: Preclinical studies identified potentially protective mechanisms, including improved insulin sensitivity, reduced inflammation, and modulation of mitochondrial function and protein turnover, but some also indicated muscle loss or proteolysis. Clinical studies reported greater reductions in fat mass than in fat-free or lean mass, neither of which represents skeletal muscle exclusively. Direct muscle and functional outcomes were assessed in few studies and yielded mixed results. Incident sarcopenia was rarely evaluated. Conclusions: GLP-1-based pharmacotherapies may influence sarcopenia risk through competing pathways. Metabolic improvements may support muscle health, whereas energy restriction, inadequate protein intake, gastrointestinal adverse effects, and lean tissue loss may increase vulnerability. Current evidence is insufficient to determine their net effect on sarcopenia risk.

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

GLP-1 TherapiesIssue #59

GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes

↗

GLP-1 Treatments and Muscle Health in Obesity: Body Weight, Muscle Strength, and Muscle Loss Outcomes

Abstract

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief